SCHEMBL666767

SCHEMBL666767

FC(F)(F)c1ccc2[nH]c(Cl)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 6/20 0.43
KIF11 P52732 3/20 0.42
KDM4E B2RXH2 2/20 0.42
METAP2 P50579 1/20 0.42
DGAT1 O75907 2/20 0.41
KCNH2 Q12809 2/20 0.41
CHUK O15111 1/20 0.41
JUN P05412 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
CBFB Q13951 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031395 0.86 MAPT (0.36) NPBWR1KIF11KDM4EMETAP2KCNH2
SCHEMBL1311258 0.86 NPBWR1 (0.58) NPBWR1DGAT1KCNH2DYRK1ADYRK1B
SCHEMBL5015652 0.82 SCN10A (0.45) KIF11METAP2KCNH2CHUKDYRK1A
SCHEMBL5681855 0.80 NPSR1 (0.59) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL2361268 0.79 NPSR1 (0.46) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL18628731 0.79 NPBWR1 (0.43) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL5679579 0.79 MAPT (0.57) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL2360716 0.79 MASP2 (0.48) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL21496795 0.79 NPBWR1 (0.43) NPBWR1KIF11KDM4EMETAP2DGAT1
SCHEMBL711944 0.79 NPBWR1 (0.43) NPBWR1KIF11KDM4EMETAP2DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620413-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2006-02-01 EP claimed
WO-2004098494-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-11-18 WO claimed
WO-2026086928-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2026-04-30 WO disclosed
US-20260070913-A1 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA INST SCI & TECH (KR) 2026-03-12 US disclosed
EP-4702017-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2026-03-04 EP disclosed
WO-2025048759-A1 BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS ICOSYN THERAPEUTICS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) 2025-03-06 WO disclosed
CN-115768761-B Novel benzimidazole derivatives 卡尔那生物科学株式会社 2025-02-25 CN disclosed
US-20240279205-A1 NOVEL BENZIMIDAZOLE DERIVATIVE CARNA BIOSCIENCES, INC. (JP) 2024-08-22 US disclosed
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2024-02-15 US disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 CN disclosed
US-20230103742-A1 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2023-04-06 US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 EP disclosed
WO-2002048152-A2 SPIRO[ISOBENZOFURAN-1,4'-PIPERIDIN]-3-ONES AND 3H-SPIROISOBENZOFURAN-1,4'-PIPERIDINES NEUROGEN CORPORATION (US) 2002-06-20 WO disclosed
EP-1098894-A1 FKBP INHIBITORS Pfizer Limited (GB) 2001-05-16 EP disclosed
US-6166011-A FKBP inhibitors PFIZER INC (US) 2000-12-26 US disclosed
WO-2000005231-A1 FKBP INHIBITORS PFIZER LIMITED (GB) 2000-02-03 WO disclosed
US-5077407-A Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles THE UPJOHN COMPANY (US) 1991-12-31 US disclosed
EP-0130729-A2 Alkylthio- and alkylsulfinyl-benzimidazole derivatives THE UPJOHN COMPANY (US) 1985-01-09 EP disclosed
US-4472409-A ANTIULCER AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1984-09-18 US disclosed
EP-0080602-A1 Substituted benzimidazoles, process for their preparation, their use and medicaments containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1983-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103742-A1 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME HASPIN, WEE2, CDK7 NPBWR1 3900/4885KIF11 274/4885KDM4E 2072/4885
US-20240279205-A1 NOVEL BENZIMIDAZOLE DERIVATIVE STING1, IRF3, TBK1 NPBWR1 1544/4885KIF11 4278/4885KDM4E 2788/4885
US-20260070913-A1 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME CSNK1A1, CKS1B, HGFAC NPBWR1 2298/4885KIF11 944/4885KDM4E 3599/4885
US-20240051970-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 NPBWR1 1928/4885KIF11 4125/4885KDM4E 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.